Score: 85.16 out of 100.00


Key points:

  • FLGT stock price looks quite attractive compared to its valuation a couple months ago
  • The company has relatively strong fundamentals
  • There are however mixed signals whether it’s a buy or not
  • The biggest concern is that it is considered a “COVID” company; while it’s last year’s profit came largely from COVID-19 testing, the company offers much more than that, including oncology-related genetic testing, with quite considerable investments in that area



Company’s website

Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. It offers genes and panels, known mutation, hereditary cancer, carrier screening, and tumor profiling solutions. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.

Continue reading “Fulgent Genetics (NASDAQ:FLGT): buy or not?”